EWTX Valuation

Edgewise Therapeutics Inc

Add to Watchlist

Advanced Chart

22.720

+2.3(11.263%)1D

EWTX Relative Valuation

EWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EWTX is overvalued; if below, it's undervalued.

Historical Valuation

Edgewise Therapeutics Inc (EWTX) is now in the Fair zone, suggesting that its current forward PS ratio of 20.42 is considered Fairly compared with the five-year average of -10.72. The fair price of Edgewise Therapeutics Inc (EWTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：22.72

Fair

-11.12

Trailing

Forward

-5.63

EV/EBITDA

Edgewise Therapeutics Inc. (EWTX) has a current EV/EBITDA of -5.63. The 5-year average EV/EBITDA is -7.09. The thresholds are as follows: Strongly Undervalued below -20.12, Undervalued between -20.12 and -13.61, Fairly Valued between -0.58 and -13.61, Overvalued between -0.58 and 5.94, and Strongly Overvalued above 5.94. The current Forward EV/EBITDA of -5.63 falls within the Historic Trend Line -Fairly Valued range.

-5.82

EV/EBIT

Edgewise Therapeutics Inc. (EWTX) has a current EV/EBIT of -5.82. The 5-year average EV/EBIT is -7.05. The thresholds are as follows: Strongly Undervalued below -20.39, Undervalued between -20.39 and -13.72, Fairly Valued between -0.38 and -13.72, Overvalued between -0.38 and 6.29, and Strongly Overvalued above 6.29. The current Forward EV/EBIT of -5.82 falls within the Historic Trend Line -Fairly Valued range.

20.42

Edgewise Therapeutics Inc. (EWTX) has a current PS of 20.42. The 5-year average PS is 0.22. The thresholds are as follows: Strongly Undervalued below -3.75, Undervalued between -3.75 and -1.77, Fairly Valued between 2.20 and -1.77, Overvalued between 2.20 and 4.19, and Strongly Overvalued above 4.19. The current Forward PS of 20.42 falls within the Strongly Overvalued range.

-11.30

P/OCF

Edgewise Therapeutics Inc. (EWTX) has a current P/OCF of -11.30. The 5-year average P/OCF is -14.64. The thresholds are as follows: Strongly Undervalued below -33.11, Undervalued between -33.11 and -23.88, Fairly Valued between -5.41 and -23.88, Overvalued between -5.41 and 3.83, and Strongly Overvalued above 3.83. The current Forward P/OCF of -11.30 falls within the Historic Trend Line -Fairly Valued range.

-10.20

P/FCF

Edgewise Therapeutics Inc. (EWTX) has a current P/FCF of -10.20. The 5-year average P/FCF is -12.75. The thresholds are as follows: Strongly Undervalued below -27.81, Undervalued between -27.81 and -20.28, Fairly Valued between -5.22 and -20.28, Overvalued between -5.22 and 2.31, and Strongly Overvalued above 2.31. The current Forward P/FCF of -10.20 falls within the Historic Trend Line -Fairly Valued range.

Edgewise Therapeutics Inc (EWTX) has a current Price-to-Book (P/B) ratio of 3.87. Compared to its 3-year average P/B ratio of 2.98 , the current P/B ratio is approximately 29.90% higher. Relative to its 5-year average P/B ratio of 2.85, the current P/B ratio is about 35.52% higher. Edgewise Therapeutics Inc (EWTX) has a Forward Free Cash Flow (FCF) yield of approximately -0.06%. Compared to its 3-year average FCF yield of -9.56%, the current FCF yield is approximately -99.36% lower. Relative to its 5-year average FCF yield of -8.20% , the current FCF yield is about -99.25% lower.

3.87

P/B

Median3y

2.98

Median5y

2.85

-0.06

FCF Yield

Median3y

-9.56

Median5y

-8.20

Competitors Valuation Multiple

The average P/S ratio for EWTX's competitors is 19.71, providing a benchmark for relative valuation. Edgewise Therapeutics Inc Corp (EWTX) exhibits a P/S ratio of 20.42, which is 3.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

EWTX.O

Edgewise Therapeutics Inc

Aurinia Pharmaceuticals Inc

15.22

8.41%

2.01B

Performance Decomposition

Market capitalization of EWTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of EWTX in the past 1 year is driven by Unknown.